HOME >> MEDICINE >> NEWS
Contrast agent puts new light on diagnosing breast cancer

ast tissue, making it harder to distinguish between healthy tissue and questionable masses in mammograms, Frangioni says.

The new agent works by binding to micro-calcifications produced in breast cancers. Though scientists cant explain exactly why these calcifications occur, studies show that the calcifications in malignant breast tumors contain a higher proportion of a particular calcium salt called hydroxyapatite. In benign tumors, the predominant calcium salt is calcium oxalate.

By homing in on hydroxyapatite, we can target these malignant cells with a high degree of specificity, and that has the potential to improve the patients outcome, Frangioni says.

The contrast agents are designed using a combination of bisphosphonate, a type of drug used to strengthen bone, with a near-infrared fluorophore. When used with optical tomography, an imaging method that transmits near-infrared light through the body, doctors can reconstruct a three-dimensional image of tissues deep inside the breast, highlighting areas where malignant tumors appear.

The agent also may be used during surgery to pinpoint the location of hydroxyapatite, and therefore the breast cancer cells themselves, Frangioni notes.

His group began working to develop agents to target hydroxyapatite six years ago, but efforts were stalled by the inability to manufacture large quantities of the agent.

It was a chemical catch22, he says. Bisphosphonates are insoluble in anything but water, but to prepare large quantities of the substance for our studies, we need to perform the reaction in the absence of water.

Last year, Frangionis chemistry group, led by Bhushan, went back to the drawing board and devised a scheme that allowed them to synthesize the agents sans water. Once the compound was completely assembled, the researchers found a way to then make it water soluble.

Recent studies by the lab proved that the new agent works well in
'"/>


26-Mar-2007


Page: 1 2 3

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. Targeted, oral agent Enzastaurin shows favorable results
3. Studies suggest investigational agent reduces disease activity in MS
4. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
5. MRI contrast agent can detect heart attack in the making
6. New reagent delivers a chemical breakthrough at FSU
7. High-resolution imaging with contrast agent shows promise in osteoarthritis research
8. Study suggests anesthetic agent may have rapid antidepressant effects
9. Alzheimers medication shows promise in treating nerve agent and pesticide poisoning
10. Cranberries contain possible anti-caries/anti-plaque agents
11. New contrast agents may be on horizon for better medical imaging

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Contrast agent puts new light diagnosing breast cancer

(Date:9/3/2015)... IN (PRWEB) , ... September 03, 2015 , ... ... Rochester, MN, and Indiana University, Indianapolis, have chosen Center for Hospice Care ... from these institutions will train at CHC as part of fulfilling their requirements ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... in Haiti, has partnered with Slingshot® Product Development Group to manufacture a long-lasting ... water. Michael Wahl with DriButts plans to bring 600 DriButts Diapers to rural ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a comprehensive survey ... and Policy Analysis has found physician leadership development training programs to be growing ... respondents said their organizations conduct some kind of physician leadership development program, another ...
(Date:9/3/2015)... , ... September 03, 2015 , ... ... community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado Bellingham, ... and has been carefully designed to serve up to 80 people living with ...
(Date:9/3/2015)... ... September 03, 2015 , ... IQ Formulations today ... by economic development group GrowFL and the Edward Lowe Foundation. The leading health ... this prestigious award, which recognizes growing second-stage companies “that demonstrate high performance in ...
Breaking Medicine News(10 mins):Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 2Health News:IQ Formulations Hailed Among Florida Companies to Watch for 2015 3
(Date:9/3/2015)... About dry eye syndrome Dry eye ... deficient tear production or quick tear evaporation or deviation ... aqueous tear deficient dry eye and evaporative dry eye. ... not produce enough tears, whereas meibomian gland dysfunction results ... slow tear evaporation and maintain tear stability. The symptoms ...
(Date:9/3/2015)... , Sept. 3, 2015  WellCare Health Plans, Inc. ... Asher , senior vice president and chief financial officer, ... 2015 Healthcare Conference on Wednesday, September 9, 2015, at ... be webcast live. In addition, a replay of the ... live broadcast. Both the live broadcast and the replay ...
(Date:9/3/2015)... ALISO VIEJO, Calif. , Sept. 3, ... a leading global pharmaceutical company, and AqueSys, Inc. ... on developing ocular implants that reduce intraocular pressure ... have entered into an agreement under which Allergan ... the terms of the agreement, Allergan will acquire ...
Breaking Medicine Technology:Global Dry Eye Syndrome Market 2015-2019 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 2Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 3Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 4Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 5Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering 6
Cached News: